Your session is about to expire
← Back to Search
Vascular Disrupting Agent
Arm 1: CA4P + Carboplatin + paclitaxel for Thyroid Cancer (FACT Trial)
Phase 2 & 3
Waitlist Available
Led By Julie A. Sosa, MD, FACS
Research Sponsored by Mateon Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomization through end of study visit
Awards & highlights
FACT Trial Summary
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
Eligible Conditions
- Thyroid Cancer
FACT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from randomization to date last known alive
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization to date last known alive
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall Survival
Secondary outcome measures
To Determine Percentage of 1 Year Survival
To Determine Progression Free Survival
FACT Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 1: CA4P + Carboplatin + paclitaxelExperimental Treatment1 Intervention
Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
Group II: Arm 2: Carboplatin + PaclitaxelActive Control2 Interventions
Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
Find a Location
Who is running the clinical trial?
Mateon TherapeuticsLead Sponsor
14 Previous Clinical Trials
557 Total Patients Enrolled
Julie A. Sosa, MD, FACSPrincipal InvestigatorYale University School of Medicine, New Haven, CT
Share this study with friends
Copy Link
Messenger